Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids ; volume:43 ; number:3 ; day:20 ; month:11 ; year:2023 ; pages:155-170 ; date:1.2024
Oncogene ; 43, Heft 3 (20.11.2023), 155-170, 1.2024

Creator
Lasolle, Hélène
Schiavo, Andrea
Tourneur, Adrien
Gillotay, Pierre
Faria da Fonseca, Bárbara de
Ceolin, Lucieli
Monestier, Olivier
Aganahi, Benilda
Chomette, Laura
Kizys, Marina Malta Letro
Haenebalcke, Lieven
Pieters, Tim
Goossens, Steven
Haigh, Jody
Detours, Vincent
Maia, Ana Luiza Silva
Costagliola, Sabine
Romitti, Mírian
Contributor
SpringerLink (Online service)

DOI
10.1038/s41388-023-02889-y
URN
urn:nbn:de:101:1-2024032515125979048784
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
14.08.2025, 10:59 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Lasolle, Hélène
  • Schiavo, Andrea
  • Tourneur, Adrien
  • Gillotay, Pierre
  • Faria da Fonseca, Bárbara de
  • Ceolin, Lucieli
  • Monestier, Olivier
  • Aganahi, Benilda
  • Chomette, Laura
  • Kizys, Marina Malta Letro
  • Haenebalcke, Lieven
  • Pieters, Tim
  • Goossens, Steven
  • Haigh, Jody
  • Detours, Vincent
  • Maia, Ana Luiza Silva
  • Costagliola, Sabine
  • Romitti, Mírian
  • SpringerLink (Online service)

Other Objects (12)

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

Response to BRAF/MEK Inhibition in A598_T599insV BRAF Mutated Melanoma

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated

The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors

The MITF/mir-579-3p regulatory axis dictates BRAF-mutated melanoma cell fate in response to MAPK inhibitors

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors

Identification of synthetic chemosensitivity genes paired with BRAF for BRAF/MAPK inhibitors

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

BRAF inhibitors in BRAF V600E-mutated ameloblastoma: systematic review of rare cases in the literature

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

Targeted therapy with vemurafenib in BRAF(V600E)-mutated anaplastic thyroid cancer

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation

PARP1 negatively regulates MAPK signaling by impairing BRAF-X1 translation

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

TERT expression is susceptible to BRAF and ETS-factor inhibition in BRAF V600E /TERT promoter double-mutated glioma

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer

Related objects